170 related articles for article (PubMed ID: 31723438)
1. Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis.
Bsteh G; Berek K; Hegen H; Buchmann A; Voortman MM; Auer M; Wurth S; Zinganell A; Di Pauli F; Deisenhammer F; Khalil M; Berger T
Mult Scler J Exp Transl Clin; 2019; 5(4):2055217319885987. PubMed ID: 31723438
[TBL] [Abstract][Full Text] [Related]
2. Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
Bsteh G; Berek K; Hegen H; Teuchner B; Buchmann A; Voortman MM; Auer M; Wurth S; Zinganell A; Di Pauli F; Deisenhammer F; Khalil M; Berger T
Mult Scler; 2020 Nov; 26(13):1682-1690. PubMed ID: 31668116
[TBL] [Abstract][Full Text] [Related]
3. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
[TBL] [Abstract][Full Text] [Related]
5. Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS.
Engel S; Steffen F; Uphaus T; Scholz-Kreisel P; Zipp F; Bittner S; Luessi F
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32019769
[TBL] [Abstract][Full Text] [Related]
6. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J;
Lancet Neurol; 2022 Mar; 21(3):246-257. PubMed ID: 35182510
[TBL] [Abstract][Full Text] [Related]
7. Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis.
Mariottini A; Marchi L; Innocenti C; Di Cristinzi M; Pasca M; Filippini S; Barilaro A; Mechi C; Fani A; Mazzanti B; Biagioli T; Materozzi F; Saccardi R; Massacesi L; Repice AM
Front Neurol; 2022; 13():820256. PubMed ID: 35280289
[TBL] [Abstract][Full Text] [Related]
8. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
Front Immunol; 2021; 12():647618. PubMed ID: 33796113
[No Abstract] [Full Text] [Related]
9. Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
Calabresi PA; Arnold DL; Sangurdekar D; Singh CM; Altincatal A; de Moor C; Engle B; Goyal J; Deykin A; Szak S; Kieseier BC; Rudick RA; Plavina T
Mult Scler; 2021 Sep; 27(10):1497-1505. PubMed ID: 33307998
[TBL] [Abstract][Full Text] [Related]
10. Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis.
Engel S; Protopapa M; Steffen F; Papanastasiou V; Nicolaou C; Protopapas M; Zipp F; Bittner S; Luessi F
Ther Adv Neurol Disord; 2021; 14():17562864211001977. PubMed ID: 33959194
[TBL] [Abstract][Full Text] [Related]
11. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
Dietmann AS; Kruse N; Stork L; Gloth M; Brück W; Metz I
J Neurol; 2023 Mar; 270(3):1416-1429. PubMed ID: 36372867
[TBL] [Abstract][Full Text] [Related]
12. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study.
Uphaus T; Steffen F; Muthuraman M; Ripfel N; Fleischer V; Groppa S; Ruck T; Meuth SG; Pul R; Kleinschnitz C; Ellwardt E; Loos J; Engel S; Zipp F; Bittner S
EBioMedicine; 2021 Oct; 72():103590. PubMed ID: 34571362
[TBL] [Abstract][Full Text] [Related]
13. Changes in serum neurofilament light chain levels following narrowband ultraviolet B phototherapy in clinically isolated syndrome.
Fabis-Pedrini MJ; Kuhle J; Roberts KMA; Trend S; Jones AP; Maceski A; Carroll WM; Lucas RM; Mastaglia FL; Hart PH; Kermode AG
Brain Behav; 2022 Feb; 12(2):e2494. PubMed ID: 35084124
[TBL] [Abstract][Full Text] [Related]
14. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
[TBL] [Abstract][Full Text] [Related]
15. Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients.
Bridel C; Verberk IMW; Heijst JJA; Killestein J; Teunissen CE
Mult Scler Relat Disord; 2021 Jan; 47():102666. PubMed ID: 33291033
[TBL] [Abstract][Full Text] [Related]
16. Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
Fujimori J; Nakashima I
J Neurol Sci; 2021 Aug; 427():117528. PubMed ID: 34098375
[TBL] [Abstract][Full Text] [Related]
17. Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis.
Loonstra FC; de Ruiter LRJ; Koel-Simmelink MJA; Schoonheim MM; Strijbis EMM; Moraal B; Barkhof F; Uitdehaag BMJ; Teunissen C; Killestein J
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36543540
[TBL] [Abstract][Full Text] [Related]
18. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
[TBL] [Abstract][Full Text] [Related]
19. Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort.
Steffen F; Uphaus T; Ripfel N; Fleischer V; Schraad M; Gonzalez-Escamilla G; Engel S; Groppa S; Zipp F; Bittner S
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411080
[TBL] [Abstract][Full Text] [Related]
20. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.
Bjornevik K; Munger KL; Cortese M; Barro C; Healy BC; Niebuhr DW; Scher AI; Kuhle J; Ascherio A
JAMA Neurol; 2020 Jan; 77(1):58-64. PubMed ID: 31515562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
